S&P 500
7,357.80
-0.44%
Dow Jones
51,945.60
-0.47%
Nasdaq 100
29,082.80
-1.56%
Russell 2000
3,005.17
-0.36%
FTSE 100
10,505.10
-0.38%
Nikkei 225
69,696.60
-2.22%
McKesson

MCK Q3 2026 Earnings

Reported Feb 4, 2026 at 4:05 PM ET · SEC Source

Q3 26 EPS

$9.34

BEAT +0.76%

Est. $9.27

Q3 26 Revenue

$106.16B

BEAT +0.23%

Est. $105.91B

vs S&P Since Q3 26

-16.2%

TRAILING MARKET

MCK -8.6% vs S&P +7.6%

Market Reaction

Did MCK Beat Earnings? Q3 2026 Results

McKesson posted a clean beat across both top and bottom lines in fiscal Q3 2026, with adjusted EPS of $9.34 edging past the $9.27 consensus estimate by 0.71% and revenue of $106.16 billion coming in ahead of the $105.91 billion expected, up 11.4% fro… Read more McKesson posted a clean beat across both top and bottom lines in fiscal Q3 2026, with adjusted EPS of $9.34 edging past the $9.27 consensus estimate by 0.71% and revenue of $106.16 billion coming in ahead of the $105.91 billion expected, up 11.4% from a year ago. The primary engine behind the quarter was the company's Oncology and Multispecialty segment, which delivered 37% revenue growth to $13.01 billion and 57% adjusted operating profit growth, fueled by specialty drug distribution and provider solutions that continue to scale rapidly. Prescription volumes from retail national account customers also drove core pharmaceutical distribution higher, underpinning the broader revenue expansion. On the outlook, McKesson raised and narrowed its fiscal 2026 adjusted EPS guidance to a range of $38.80 to $39.20, implying 17% to 19% growth versus the prior year, a signal of management confidence that analysts have largely embraced, with a "Strong Buy" consensus emerging following the report.

Key Takeaways

  • • Increased prescription transaction volumes from retail national account customers
  • • Growth in distribution of oncology and multispecialty products including contributions from acquisitions
  • • Growth in provider solutions and specialty distribution in Oncology & Multispecialty segment
  • • Higher demand for access solutions in Prescription Technology Solutions
  • • Pre-tax credit of $160 million related to Rite Aid bankruptcy boosting GAAP results
  • • Share repurchases reducing diluted share count from 126.6 million to 123.7 million
24/7 Wall St

MCK YoY Financials

Q3 2026 vs Q3 2025, source: SEC Filings

24/7 Wall St

MCK Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 26 Q4 26

“McKesson delivered another strong quarter, extending the momentum we've built across the enterprise and demonstrating the impact of our disciplined execution. Our results highlight the strength of our core distribution businesses and the meaningful progress we are making against our strategic priorities.”

— Brian Tyler, Q3 2026 Earnings Press Release

Back to MCK Stock Page